Goldman Sachs: Edge Medical's Overseas Growth in Line with Expectations; Maintains Buy Rating with HK$81 Target Price

Overview

This report summarizes key takeaways from Goldman Sachs’ meeting with Edge Medical (2675.HK) at the Asia Communacopia + Technology conference. The core conclusion is positive: the firm believes the company has a clear overseas growth path with high order visibility, maintaining its 'Buy' rating and HK$81.0 target price. Management reaffirmed FY26 financial guidance, including approximately RMB 850 million in revenue and achieving breakeven. The report details the company’s overseas channel strategy, four key differentiators versus competitors (e.g., da Vinci), and its future product roadmap, while highlighting risks such as commercialization pace and overseas partner capabilities.

Core views

Overseas operations have become the company’s primary growth engine, contributing ~60% of revenue in 2025, with Europe, South America, and Southeast Asia/Middle East/Africa each accounting for roughly one-third. Looking ahead to 2026, management expects incremental contributions from India and Southern Europe, with new orders from the UK, France, Germany, Japan, and South Korea anticipated to commence in 2027. Supported by clear order visibility, management is confident in achieving ~120 commercial installations in FY26 (vs. 72 in 2025), with 60 expected by June 30. Backed by this execution progress, the company maintains its FY26 revenue guidance of ~RMB 850 million and full-year breakeven target. In terms of overseas expansion, the company adheres to a 'distributor-led model supplemented by direct sales in mature markets.' Most international markets are advanced through local distributors—many of whom previously distributed CMR surgical robots or operated in adjacent fields like imaging or surgical equipment. Simultaneously, for developing markets such as the UK, France, and Germany, the company is selectively building direct sales teams and local capabilities. The overseas team is expected to expand from its current size of 50–60 to 80–100 personnel to support commercialization. On product competitiveness, management highlighted four key advantages over the da Vinci system: (1) Cost-effectiveness—devices and consumables are priced ~30% lower than da Vinci while delivering comparable clinical performance; (2) Remote surgery functionality—used for physician training and replacing the need for expert travel; with standardized remote surgery fees now piloted in Hunan and Guangdong provinces at RMB 16,000–26,000, this pricing could accelerate domestic adoption; (3) A 'single-port + multi-port' combo platform—domestically, hospitals gain multiple functionalities under one procurement quota; overseas, premium customers receive dual-mode capabilities comparable to da Vinci Xi but pay only one service fee, offering significant cost savings; (4) Continuous product iteration—with a next-gen product对标 da Vinci 5 slated for 2027 and an AI-integrated Jingfeng Gen 6 expected around 2030.

Analysis framework

As a conference minutes-style report, this analysis employs an 'event-driven + fundamental validation' framework. The firm first confirmed near-term operational certainty (e.g., H1 installation volume, full-year guidance) through executive dialogue, alleviating market concerns about overseas expansion uncertainty. It then translated qualitative insights into quantitative anchors (e.g., 120 installations, RMB 850M revenue) as key inputs for valuation modeling. Finally, it dissected competitive product attributes (price, functionality, service pricing model) to assess the sustainability of market share gains in a mature landscape. This logical chain—from 'management confidence' to 'financial delivery' to 'moat validation'—exemplifies a typical event-tracking research paradigm.

Methodology notes

• Valuation MethodDCF (Discounted Cash Flow)

  Absolute valuation based on free cash flow discounting

  The report uses a DCF model to derive the target price, assuming a WACC of 9% and a terminal growth rate of 3%. These parameters align with Goldman Sachs’ assumptions for other healthcare tech and services coverage, ensuring cross-asset valuation consistency and helping readers understand the underlying assumptions behind the target price.

• Industry/Value Chain Analysis FrameworkValue chain analysis

  Analyzing competitive advantage through channel structure and end-user service models

  Beyond product specs, the report deeply examines the logic behind 'distributor vs. direct sales' channel choices and differences between 'single-service-fee vs. recurring-fee' models. This highlights that in medical device globalization, commercial ecosystem construction—not just technical parameters—is a critical determinant of market share.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Edge Medical (2675.HK)

  Primary coverage asset; benefits from overseas order ramp-up and product iteration

  Strengths

  High and geographically balanced overseas revenue share, clear cost advantage, remote surgery aligned with policy direction, well-defined product roadmap

  Weaknesses

  Still transitioning from losses to profitability; overseas reliance on distributors poses control challenges

  Comparison

  Offers significant cost advantages and service model innovation vs. legacy players like da Vinci; earlier and more diversified overseas presence compared to other domestic peers

  Risks

  Slower-than-expected domestic commercialization, overseas IP litigation risk, underperforming distributors, production capacity constraints

Key data

• FY26E Revenue Guidance~RMB 850 millionManagement reaffirmed unchanged guidance, supported by order visibility
• FY26E Installation Target~120 units72 units in 2025; 60 expected by June 30
• Overseas Revenue Share~60%2025 figure; Europe/South America/Southeast Asia each ~1/3
• Price Discount vs. da Vinci~30%Applies to both devices and consumables; clinical performance remains comparable
• Remote Surgery Fee RangeRMB 16,000–26,000Standardized pilot pricing implemented in Hunan and Guangdong
• 12-Month Target PriceHK$81.0Based on DCF valuation; current price HK$50.10 implies 61.7% upside

Impact & implications

The report argues that Edge Medical’s disciplined overseas expansion and clear breakeven guidance for FY26 enhance the credibility of earnings delivery. Its competitive strategy—'high cost-effectiveness + remote surgery + combo platform'—could accelerate domestic and global adoption of Chinese surgical robots amid healthcare cost containment and resource decentralization trends. If the next-gen product (2027) and subsequent AI-enhanced version (around 2030) launch as scheduled, the company could further solidify its technological lead. For investors, current valuations reflect high growth expectations, necessitating close monitoring of quarterly installation data and overseas distributor conversion efficiency.

Risks

• Slower-than-expected domestic commercialization in China
• Potential overseas intellectual property litigation risks
• Underperformance by overseas distribution partners
• Production capacity constraints affecting deliveries

What to watch

• Achievement of H1 2026 target of 60 installations
• Pace of incremental contributions from India and Southern Europe
• Validation signals for new market orders (UK, France, Germany, Japan, South Korea) starting in 2027
• R&D and regulatory progress for next-gen product对标 da Vinci 5